Advertisement

Immune Checkpoint Inhibitors in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer

Lung Cancer (HA Wakelee, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Lung Cancer

Opinion statement

Surgical resection ± chemotherapy ± radiation or stereotactic body radiation therapy (SBRT) are established treatment modalities for resectable stage non-small cell lung cancer (NSCLC), and concurrent chemotherapy with radiation is the therapy of choice for unresectable locally advanced disease. Despite treatment with curative intent, most patients subsequently relapse and develop distant disease. Treatment with checkpoint inhibitors represents a major advancement in the treatment of metastatic NSCLC. Therapy against programed cell death-1/programmed cell death ligand 1 (PD-1/PD-L1) is associated with a significant improvement in overall survival in stage IV disease, and these results have led to a great interest in evaluating these agents in earlier-stage NSCLC. The preliminary data from ongoing trials suggest that the integration of checkpoint blockage into the treatment of early-stage and locally advanced NSCLC is safe, tolerable, and has the potential to improve outcomes without adding substantial toxicity. In the current review, we provide an overview of the emerging data on the role of PD-1/PD-L1 and cytotoxic T lymphocyte-associated protein 4 (CTLA-4) inhibitors in the treatment of early-stage and locally advanced NSCLC, with a focus on ongoing clinical trials and combination strategies.

Keywords

Checkpoint inhibitors Adjuvant Neoadjuvant Non-small cell lung cancer 

Notes

Acknowledgements

We thank Sonya J. Smyk, Moffitt Cancer Center, for editorial support. She received no compensation beyond her regular salary.

Compliance with Ethical Standards

Conflict of Interest

Sonam Puri declares that she has no conflict of interest. Michael Shafique has served on advisory boards for GlaxoSmithKline. Jhanelle E. Gray has received research funding through grants from Merck, AstraZeneca, Genentech, and Bristol-Myers Squibb, and has served on advisory boards for AstraZeneca.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Ryerson AB, Eheman CR, Altekruse SF, Ward JW, Jemal A, Sherman RL, et al. Annual Report to the Nation on the Status of Cancer, 1975–2012, featuring the increasing incidence of liver cancer. Cancer. 2016;122(9):1312–37.  https://doi.org/10.1002/cncr.29936.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Howlader N NA, Krapcho M, Miller D, Bishop K, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975–2014, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2014/, based on November 2016 SEER data submission, posted to the SEER web site, April 2017.
  3. 3.
    Qiang G, Guo Y, Xiao F, Yu Q, Liang C, Song Z, et al. Analyses of risk factors for postoperative recurrence after curative resection of stage III A-N2 non-small cell lung cancer. Zhonghua Yi Xue Za Zhi. 2014;94(41):3239–43.PubMedGoogle Scholar
  4. 4.
    Goldstraw PI, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al. The IASLC lung Cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol. 2007;2:706–14.CrossRefPubMedGoogle Scholar
  5. 5.
    Administration USFaD. FDA expands approved use of Opdivo in advanced lung cancer. FDA. 2015. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm466413.htm. Accessed 25 April 2017.
  6. 6.
    Administration USFaD. Pembrolizumab (KEYTRUDA) Checkpoint Inhibitor. FDA. 2016. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm526430.htm. Accessed 25 April 2017.
  7. 7.
    Administration USFaD. Atezolizumab (TECENTRIQ). FDA. 2016. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm525780.htm. Accessed 25 Apiril 2017.
  8. 8.
    •• Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung Cancer. N Engl J Med. 2017;377(20):1919–29.  https://doi.org/10.1056/NEJMoa1709937. This article describes the results of a large phase III trial evaluating the use of durvalumab versus placebo as consolidation therapy after CCR in unresectable stage III NSCLC.CrossRefPubMedGoogle Scholar
  9. 9.
    Administration USFaD. FDA approves durvalumab after chemoradiation for unresectable stage III NSCLC. 2018. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm597248.htm. Accessed 4/15/2018.
  10. 10.
    Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123–35.  https://doi.org/10.1056/NEJMoa1504627.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627–39.  https://doi.org/10.1056/NEJMoa1507643.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016;387(10030):1837–46.  https://doi.org/10.1016/S0140-6736(16)00587-0.CrossRefPubMedGoogle Scholar
  13. 13.
    Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–33.  https://doi.org/10.1056/NEJMoa1606774.CrossRefPubMedGoogle Scholar
  14. 14.
    Menzies AM, Rozeman EA, Amaria RN, Scolyer RA, Tetzlaff MT, Guminski A, et al. Preliminary results from the international neoadjuvant melanoma consortium (INMC). J Clin Oncol. 2017;35(15_suppl):9581.  https://doi.org/10.1200/JCO.2017.35.15_suppl.9581.Google Scholar
  15. 15.
    Scott WJ, Howington J, Feigenberg S, Movsas B, Pisters K. Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132(3 Suppl):234s–42s.  https://doi.org/10.1378/chest.07-1378.CrossRefPubMedGoogle Scholar
  16. 16.
    Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE collaborative group. J Clin Oncol. 2008;26(21):3552–9.  https://doi.org/10.1200/jco.2007.13.9030. CrossRefPubMedGoogle Scholar
  17. 17.
    Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004;350(4):351–60.  https://doi.org/10.1056/NEJMoa031644.CrossRefPubMedGoogle Scholar
  18. 18.
    Wang EH, Corso CD, Rutter CE, Park HS, Chen AB, Kim AW, et al. Postoperative radiation therapy is associated with improved overall survival in incompletely resected stage II and III non-small-cell lung cancer. J Clin Oncol. 2015;33(25):2727–34.  https://doi.org/10.1200/jco.2015.61.1517.CrossRefPubMedGoogle Scholar
  19. 19.
    Douillard JY, Rosell R, De Lena M, Riggi M, Hurteloup P, Mahe MA. Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the adjuvant Navelbine International Trialist Association (ANITA) randomized trial. Int J Radiat Oncol Biol Phys. 2008;72(3):695–701.  https://doi.org/10.1016/j.ijrobp.2008.01.044.CrossRefPubMedGoogle Scholar
  20. 20.
    Boyd JA, Hubbs JL, Kim DW, Hollis D, Marks LB, Kelsey CR. Timing of local and distant failure in resected lung cancer: implications for reported rates of local failure. J Thorac Oncol. 2010;5(2):211–4.  https://doi.org/10.1097/JTO.0b013e3181c20080. CrossRefPubMedGoogle Scholar
  21. 21.
    Group N-sCLCC. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ (Clin Res Ed). 1995;311(7010):899–909.CrossRefGoogle Scholar
  22. 22.
    Lavin Y, Kobayashi S, Leader A, Amir ED, Elefant N, Bigenwald C, et al. Innate immune landscape in early lung adenocarcinoma by paired single-cell analyses. Cell. 2017;169(4):750–65.e17.  https://doi.org/10.1016/j.cell.2017.04.014.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Vansteenkiste J, Zielinski M, Linder A, Dahabreh J, Gonzalez EE, Malinowski W, et al. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. J Clin Oncol. 2013;31(19):2396–403.  https://doi.org/10.1200/jco.2012.43.7103. CrossRefPubMedGoogle Scholar
  24. 24.
    Pujol JL, Vansteenkiste JF, De Pas TM, Atanackovic D, Reck M, Thomeer M, et al. Safety and immunogenicity of MAGE-A3 cancer immunotherapeutic with or without adjuvant chemotherapy in patients with resected stage IB to III MAGE-A3-positive non-small-cell lung cancer. J Thorac Oncol. 2015;10(10):1458–67.  https://doi.org/10.1097/jto.0000000000000653. CrossRefPubMedGoogle Scholar
  25. 25.
    Nemunaitis J, Dillman RO, Schwarzenberger PO, Senzer N, Cunningham C, Cutler J, et al. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J Clin Oncol. 2006;24(29):4721–30.  https://doi.org/10.1200/jco.2005.05.5335.CrossRefPubMedGoogle Scholar
  26. 26.
    • Liu J, Blake SJ, Yong MC, Harjunpaa H, Ngiow SF, Takeda K, et al. Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease. Cancer Discov. 2016;6(12):1382–99.  https://doi.org/10.1158/2159-8290.cd-16-0577. This article describes a preclinical study evaluating efficacy of neoadjuvant and adjuvant immunotherapy in murine model of triple negative breast cancer.CrossRefPubMedGoogle Scholar
  27. 27.
    •• Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD et al. Neoadjuvant PD-1 blockade in resectable Lung Cancer. N Engl J Med. 2018;0(0):null.  https://doi.org/10.1056/NEJMoa1716078 This article describes the results from the pilot study evaluatiing safety and feasibility of neoadjuvant nivolumab in patients with resectable stage I-IIIA NSCLC.
  28. 28.
    Groome PA, Bolejack V, Crowley JJ, Kennedy C, Krasnik M, Sobin LH, et al. The IASLC lung cancer staging project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol. 2007;2(8):694–705.  https://doi.org/10.1097/JTO.0b013e31812d05d5. CrossRefPubMedGoogle Scholar
  29. 29.
    Bezjak A, Temin S, Franklin G, Giaccone G, Govindan R, Johnson ML, et al. Definitive and adjuvant radiotherapy in locally advanced non-small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline endorsement of the American Society for Radiation Oncology evidence-based clinical practice guideline. J Clin Oncol. 2015;33(18):2100–5.  https://doi.org/10.1200/JCO.2014.59.2360. CrossRefPubMedGoogle Scholar
  30. 30.
    Socinski MA, Rosenman JG, Halle J, Schell MJ, Lin Y, Russo S, et al. Dose-escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/paclitaxel in unresectable stage IIIA/B nonsmall cell lung carcinoma: a modified phase I/II trial. Cancer. 2001;92(5):1213–23.CrossRefPubMedGoogle Scholar
  31. 31.
    Senan S, Brade A, Wang LH, Vansteenkiste J, Dakhil S, Biesma B, et al. PROCLAIM: randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 2016;34(9):953–62.  https://doi.org/10.1200/JCO.2015.64.8824.CrossRefPubMedGoogle Scholar
  32. 32.
    Santana-Davila R, Devisetty K, Szabo A, Sparapani R, Arce-Lara C, Gore EM, et al. Cisplatin and etoposide versus carboplatin and paclitaxel with concurrent radiotherapy for stage III non-small-cell lung cancer: an analysis of veterans health administration data. J Clin Oncol. 2015;33(6):567–74.  https://doi.org/10.1200/JCO.2014.56.2587.CrossRefPubMedGoogle Scholar
  33. 33.
    Ezer N, Smith CB, Galsky MD, Mhango G, Gu F, Gomez J, et al. Cisplatin vs. carboplatin-based chemoradiotherapy in patients >65 years of age with stage III non-small cell lung cancer. Radiother Oncol. 2014;112(2):272–8.  https://doi.org/10.1016/j.radonc.2014.07.014.CrossRefPubMedGoogle Scholar
  34. 34.
    Belani CP, Choy H, Bonomi P, Scott C, Travis P, Haluschak J, et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol. 2005;23(25):5883–91.  https://doi.org/10.1200/JCO.2005.55.405. CrossRefPubMedGoogle Scholar
  35. 35.
    Vokes EE, Herndon JE 2nd, Kelley MJ, Cicchetti MG, Ramnath N, Neill H, et al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol. 2007;25(13):1698–704.  https://doi.org/10.1200/JCO.2006.07.3569. CrossRefPubMedGoogle Scholar
  36. 36.
    Gandara DR, Chansky K, Albain KS, Gaspar LE, Lara PN Jr, Kelly K, et al. Long-term survival with concurrent chemoradiation therapy followed by consolidation docetaxel in stage IIIB non-small-cell lung cancer: a phase II southwest oncology group study (S9504). Clin Lung Cancer. 2006;8(2):116–21.  https://doi.org/10.3816/CLC.2006.n.039.CrossRefPubMedGoogle Scholar
  37. 37.
    Hanna N, Neubauer M, Yiannoutsos C, McGarry R, Arseneau J, Ansari R, et al. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier oncology group and U.S. Oncology. J Clin Oncol. 2008;26(35):5755–60.  https://doi.org/10.1200/JCO.2008.17.7840. CrossRefPubMedGoogle Scholar
  38. 38.
    Kelly K, Chansky K, Gaspar LE, Albain KS, Jett J, Ung YC, et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol. 2008;26(15):2450–6.  https://doi.org/10.1200/JCO.2007.14.4824.CrossRefPubMedGoogle Scholar
  39. 39.
    Wozniak AJ, Moon J, Thomas CR Jr, Kelly K, Mack PC, Gaspar LE, et al. A pilot trial of cisplatin/etoposide/radiotherapy followed by consolidation docetaxel and the combination of bevacizumab (NSC-704865) in patients with inoperable locally advanced stage III non-small-cell lung cancer: SWOG S0533. Clin Lung Cancer. 2015;16(5):340–7.  https://doi.org/10.1016/j.cllc.2014.12.014.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015;16(2):187–99.  https://doi.org/10.1016/S1470-2045(14)71207-0.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Hoang T, Dahlberg SE, Schiller JH, Mehta MP, Fitzgerald TJ, Belinsky SA, et al. Randomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III non-small-cell lung cancer: the ECOG 3598 study. J Clin Oncol. 2012;30(6):616–22.  https://doi.org/10.1200/JCO.2011.36.9116. CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Giaccone G, Bazhenova LA, Nemunaitis J, Tan M, Juhasz E, Ramlau R, et al. A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer. Eur J Cancer (Oxford, England : 1990). 2015;51(16):2321–9.  https://doi.org/10.1016/j.ejca.2015.07.035. CrossRefGoogle Scholar
  43. 43.
    Albain KS, Swann RS, Rusch VW, Turrisi AT 3rd, Shepherd FA, Smith C, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet. 2009;374(9687):379–86.  https://doi.org/10.1016/S0140-6736(09)60737-6.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Curran WJ Jr, Paulus R, Langer CJ, Komaki R, Lee JS, Hauser S, et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst. 2011;103(19):1452–60.  https://doi.org/10.1093/jnci/djr325.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Liang J, Bi N, Wu S, Chen M, Lv C, Zhao L, et al. Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial. Ann Oncol. 2017;28(4):777–83.  https://doi.org/10.1093/annonc/mdx009. PubMedGoogle Scholar
  46. 46.
    Mole RH. Whole body irradiation; radiobiology or medicine? Br J Radiol. 1953;26(305):234–41.  https://doi.org/10.1259/0007-1285-26-305-234.CrossRefPubMedGoogle Scholar
  47. 47.
    Formenti SC, Demaria S. Systemic effects of local radiotherapy. Lancet Oncol. 2009;10(7):718–26.  https://doi.org/10.1016/S1470-2045(09)70082-8.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Blanquicett C, Saif MW, Buchsbaum DJ, Eloubeidi M, Vickers SM, Chhieng DC, et al. Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: clinical implications of abscopal effects. Clin Cancer Res. 2005;11(24 Pt 1):8773–81.  https://doi.org/10.1158/1078-0432.CCR-05-0627. CrossRefPubMedGoogle Scholar
  49. 49.
    Demaria S, Ng B, Devitt ML, Babb JS, Kawashima N, Liebes L, et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys. 2004;58(3):862–70.  https://doi.org/10.1016/j.ijrobp.2003.09.012.CrossRefPubMedGoogle Scholar
  50. 50.
    Shiraishi K, Ishiwata Y, Nakagawa K, Yokochi S, Taruki C, Akuta T, et al. Enhancement of antitumor radiation efficacy and consistent induction of the abscopal effect in mice by ECI301, an active variant of macrophage inflammatory protein-1alpha. Clin Cancer Res. 2008;14(4):1159–66.  https://doi.org/10.1158/1078-0432.CCR-07-4485.CrossRefPubMedGoogle Scholar
  51. 51.
    Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, Wansley EK, et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med. 2006;203(5):1259–71.  https://doi.org/10.1084/jem.20052494.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Chakraborty M, Abrams SI, Camphausen K, Liu K, Scott T, Coleman CN, et al. Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J Immunol. 2003;170(12):6338–47.CrossRefPubMedGoogle Scholar
  53. 53.
    Kersten K, Salvagno C, de Visser KE. Exploiting the immunomodulatory properties of chemotherapeutic drugs to improve the success of cancer immunotherapy. Front Immunol. 2015;6:516.  https://doi.org/10.3389/fimmu.2015.00516.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Wu CY, Yang LH, Yang HY, Knoff J, Peng S, Lin YH, et al. Enhanced cancer radiotherapy through immunosuppressive stromal cell destruction in tumors. Clin Cancer Res. 2014;20(3):644–57.  https://doi.org/10.1158/1078-0432.CCR-13-1334.CrossRefPubMedGoogle Scholar
  55. 55.
    Dovedi SJ, Adlard AL, Lipowska-Bhalla G, McKenna C, Jones S, Cheadle EJ, et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res. 2014;74(19):5458–68.  https://doi.org/10.1158/0008-5472.CAN-14-1258.CrossRefPubMedGoogle Scholar
  56. 56.
    Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krzakowski M, et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15(1):59–68.  https://doi.org/10.1016/S1470-2045(13)70510-2.CrossRefPubMedGoogle Scholar
  57. 57.
    Katakami N, Hida T, Nokihara H, Imamura F, Sakai H, Atagi S, et al. Phase I/II study of tecemotide as immunotherapy in Japanese patients with unresectable stage III non-small cell lung cancer. Lung Cancer. 2017;105:23–30.  https://doi.org/10.1016/j.lungcan.2017.01.007.CrossRefPubMedGoogle Scholar
  58. 58.
    Boyer MJ, Gu L, Wang X, Kelsey CR, Yoo DS, Onaitis MW, et al. Toxicity of definitive and post-operative radiation following ipilimumab in non-small cell lung cancer. Lung Cancer. 2016;98:76–8.  https://doi.org/10.1016/j.lungcan.2016.05.014.CrossRefPubMedGoogle Scholar
  59. 59.
    Hellmann MD, Rizvi NA, Goldman JW, Gettinger SN, Borghaei H, Brahmer JR, et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol. 2017;18(1):31–41.  https://doi.org/10.1016/s1470-2045(16)30624-6.CrossRefPubMedGoogle Scholar
  60. 60.
    Antonia SJ, Kim SW, Apira AI. Safety and clinical activity of durvalumab (MEDI4736), an anti-PD-LI antibody, in treatment-naive patients with advanced non-small-cell lung cancer. J Clin Oncol. 2016;34(Suppl):8032.Google Scholar
  61. 61.
    Lee CK, Man J, Lord S, Links M, Gebski V, Mok T, et al. Checkpoint inhibitors in metastatic EGFR-mutated non-small cell lung cancer—a meta-analysis. J Thorac Oncol. 2017;12(2):403–7.  https://doi.org/10.1016/j.jtho.2016.10.007. CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Sonam Puri
    • 1
  • Michael Shafique
    • 2
  • Jhanelle E. Gray
    • 2
  1. 1.Department of Internal Medicine, Division of Hematology and OncologyH. Lee Moffitt Cancer Center and Research Institute/University of South FloridaTampaUSA
  2. 2.Department of Thoracic OncologyH. Lee Moffitt Cancer Center and Research InstituteTampaUSA

Personalised recommendations